Modulating cGMP to treat lung diseases

Handbook of Experimental Pharmacology

Volumn 191, Issue , 2009, Pages 469-483

  Ghofrani, Hossein Ardeschir ^a   Grimminger, Friedrich ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ADENYLATE CYCLASE; ANTIHYPERTENSIVE AGENT; BAY 63 2521; BRAIN NATRIURETIC PEPTIDE; CYCLIC AMP; CYCLIC GMP; GUANYLATE CYCLASE; ILOPROST; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 11; PHOSPHODIESTERASE I; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; CELL RECEPTOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; SOLUBLE GUANYLYL CYCLASE;

ADAPTATION; ADULT RESPIRATORY DISTRESS SYNDROME; ARTERIAL OXYGEN SATURATION; CHRONIC DISEASE; CHRONIC DRUG ADMINISTRATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME SYNTHESIS; EXERCISE; GAS EXCHANGE; HEART OUTPUT; HOMEOSTASIS; HUMAN; LUNG BLOOD FLOW; LUNG CIRCULATION; LUNG HEMODYNAMICS; LUNG PERFUSION; LUNG VASCULAR RESISTANCE; LUNG VENTILATION; LUNG VENTILATION DISTRIBUTION; NONHUMAN; OPTIMAL DRUG DOSE; OXIDATION REDUCTION REACTION; OXYGENATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REPEATED DRUG DOSE; RESPIRATORY EPITHELIUM; REVIEW; SECOND MESSENGER; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADMINISTRATION, INHALATION; ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG DELIVERY SYSTEMS; GUANYLATE CYCLASE; HUMANS; LUNG DISEASES; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PULMONARY CIRCULATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 61749097037     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-68964-5_20     Document Type: Review

References (73)

1. Abrams D, Schulze-Neick I, Magee AG (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84:E4
2. Agusti AG, Rodriguez-Roisin R (1993) Effect of pulmonary hypertension on gas exchange. Eur Respir J 6:1371-1377
3. Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ (1991) Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 308:191-197
4. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748
5. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr (2003) Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 107: 686-689
6. Bohle RM, Hartmann E, Kinfe T, Ermert L, Seeger W, Fink L (2000) Cell type-specific mRNA quantitation in non-neoplastic tissues after laser-assisted cell picking. Pathobiology 68: 191-195
7. Carlsen J, Kjeldsen K, Gerstoft J (2002) Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 16:1568-1569
8. Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF, Moser KM (1996) Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 109:1545-1549
9. Cohen AH, Hanson K, Morris K, Fouty B, McMurty IF, Clarke W, Rodman DM (1996) Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 97:172-179
10. Corbin JD, Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56:453-459
11. Egan JJ (1999) New treatments for pulmonary fibrosis? Lancet 354:1839-1840
12. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM (2004) Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110:2253-2259
13. Francis SH, Chu DM, Thomas MK, Beasley A, Grimes K, Busch JL, Turko IV, Haik TL, Corbin JD (1998) Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases. Methods 14:81-92
14. Friebe A, Koesling D (1998) Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 53:123-127
15. Friebe A, Schultz G, Koesling D (1996) Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J 15:6863-6868
16. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D (1998) YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 54:962-967
17. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157
18. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127:195-203
19. German Z, Chambliss KL, Pace MC, Arnet UA, Lowenstein CJ, Shaul PW(2000) Molecular basis of cell-specific endothelial nitric-oxide synthase expression in airway epithelium. J Biol Chem 275:8183-8189
20. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002a) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515-522
21. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002b) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360:895-900
22. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F (2003a) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42: 158-164
23. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, Seeger W, Grimminger F (2003b) Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167:1139-1141
24. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2004) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44: 1488-1496
25. Gopal VK, Francis SH, Corbin JD (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 268:3304-3312
26. Grimminger F, Spriestersbach R, Weissmann N, Walmrath D, Seeger W (1995) Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol 78: 1509-1515
27. Hassoun PM, Filippov G, Fogel M, Donaldson C, Kayyali US, Shimoda LA, Bloch KD (2004) Hypoxia decreases expression of soluble guanylate cyclase in cultured rat pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 30:908-913
28. Higenbottam T, Siddons T, Demoncheaux E (2000) A therapeutic role for chronic inhaled nitric oxide? Lancet 356:446-447
29. Hillier SC, Graham JA, Hanger CC, Godbey PS, Glenny RW, Wagner WW Jr (1997) Hypoxic vasoconstriction in pulmonary arterioles and venules. J Appl Physiol 82:1084-1090
30. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342:1866-1870
31. Huai Q, Liu Y, Francis SH, Corbin JD, Ke H (2004) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J Biol Chem 279:13095-13101
32. Ide H, Nakano H, Ogasa T, Osanai S, Kikuchi K, Iwamoto J (1999) Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide. J Appl Physiol 87:1629-1636
33. Kothari SS, Duggal B (2002) Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 54:404-409
34. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2002) Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 90:677-680
35. Li D, Zhou N, Johns RA (1999) Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am J Physiol 277:L841-L847
36. Li D, Laubach VE, Johns RA (2001) Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS Am J Physiol Lung Cell Mol Physiol 281: L369-L376
37. Melot C, Lejeune P, Leeman M, Moraine JJ, Naeije R (1989) Prostaglandin E1 in the adult respiratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis 139:106-110
38. Michelakis E, TymchakW, Lien D,Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398-2403
39. Michelakis ED, TymchakW, Noga M,Webster L,Wu XC, Lien D,Wang SH, Modry D, Archer SL (2003) Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108:2066-2069
40. Moncada I, Jara J, Subira D, Castano I, Hernandez C (2004) Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 46:357-360
41. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D (2003) Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 160:719-727
42. Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R (1997) Effect of YC-1, an NOindependent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120:681-689
43. Oliver J, Webb DJ (2002) Sildenafil for "blue babies". Such unlicensed drug use might be justified as last resort. BMJ 325:1174
44. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124:820-824
45. Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Wollbruck B, Grimminger F, Seeger W (1998) Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 24:631-634
46. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W (1999) Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160:600-607
47. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM, Behr J, Kleber FX, SeegerW(2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132:435-443
48. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322-329
49. Patole S, Travadi J (2002) Sildenafil for "blue babies". Ethics, conscience, and science have to be balanced against limited resources. BMJ 325:1174
50. Prasad S,Wilkinson J, Gatzoulis MA (2000) Sildenafil in primary pulmonary hypertension. N Engl J Med 343:1342
51. Radermacher P, Santak B, Becker H, Falke KJ (1989) Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 70:601-606
52. Reichenberger F, Voswinckel R, Enke B, Rutsch M, Fechtali EE, Schmehl T, Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, Grimminger F, Mayer E, Seeger W (2007) Longterm treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 30:922-927
53. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM (1993) Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 328:399-405
54. Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111-117
55. Sastry BK, Narasimhan C, Reddy NK, Anand B, Prakash GS, Raju PR, Kumar DN (2002) A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 54:410-414
56. Sastry BK, Narasimhan C, Reddy NK, Raju BS (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43:1149-1153
57. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, Grimminger F, Seeger W, Walmrath D (2000) Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 292:512-520
58. Schumacher YO, Zdebik A, Huonker M, Kreisel W (2001) Sildenafil in HIV-related pulmonary hypertension. AIDS 15:1747-1748
59. Singh B, Gupta R, Punj V, Ghose T, Sapra R, Grover DN, Kaul U (2002) Sildenafil in the management of primary pulmonary hypertension. Indian Heart J 54:297-300
60. Stasch JP, Becker EM, onso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature 410:212-215
61. Stasch JP, Schmidt P, onso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F (2002) NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136:773-783
62. Straub A, Stasch JP, onso-Alija C, et-Buchholz J, Ducke B, Feurer A, Furstner C (2001) NOindependent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 11:781-784
63. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC (1997) YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 320: 161-166
64. Von Euler US, Liljestrand G (1946) Observations on the pulmonary arterial blood pressure in the cat. Acta Physiol Scand 12:301-320
65. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W (1993) Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 342:961-962
66. Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H (2002) Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71:398-402
67. Wegener JW, Nawrath H (1997) Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Eur J Pharmacol 323:89-91
68. Weissmann N, Voswinckel R, Tadic A, Hardebusch T, Ghofrani HA, Schermuly RT, Seeger W, Grimminger F (2000) Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs. Am J Respir Cell Mol Biol 23:222-227
69. Weissmann N, Grimminger F, Olschewski A, Seeger W (2001) Hypoxic pulmonary vasoconstriction: a multifactorial response? Am J Physiol Lung Cell Mol Physiol 281:L314-L317
70. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218-1222
71. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM (1995) YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116: 1973-1978
72. Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR (2003) Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation 107:234-237
73. Zimmermann AT, Calvert AF, Veitch EM (2002) Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension. Intern Med J 32:424-426